APO Research
Talk to an analyst

APO RESEARCH · REPORT

Aneurysmal Subarachnoid Hemorrhage Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Aneurysmal Subarachnoid Hemorrhage Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025197 pages

Choose your research edition.

Industry ResearchAneurysmal Subarachnoid Hemorrhage Drugs Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Aneurysmal Subarachnoid Hemorrhage Drugs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Aneurysmal Subarachnoid Hemorrhage Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Aneurysmal Subarachnoid Hemorrhage Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Aneurysmal Subarachnoid Hemorrhage Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Aneurysmal Subarachnoid Hemorrhage Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Aneurysmal Subarachnoid Hemorrhage Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Aneurysmal Subarachnoid Hemorrhage Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Aneurysmal Subarachnoid Hemorrhage Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Aneurysmal Subarachnoid Hemorrhage Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Aneurysmal Subarachnoid Hemorrhage Drugs include Arbor Pharmaceuticals, Orexo AB, PDS Biotechnology Corporation, Pharmaxis, Purdue Pharma, Pfizer, Mylan N.V, Johnson and Johnson and Sun Pharmaceutical Industries, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Aneurysmal Subarachnoid Hemorrhage Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Aneurysmal Subarachnoid Hemorrhage Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Aneurysmal Subarachnoid Hemorrhage Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Aneurysmal Subarachnoid Hemorrhage Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Aneurysmal Subarachnoid Hemorrhage Drugs Segment by Company

Arbor Pharmaceuticals

Orexo AB

PDS Biotechnology Corporation

Pharmaxis

Purdue Pharma

Pfizer

Mylan N.V

Johnson and Johnson

Sun Pharmaceutical Industries

Teva Pharmaceutical

Aneurysmal Subarachnoid Hemorrhage Drugs Segment by Type

Osmotic Agent

Anticonvulsant

Calcium Channel Blocker

Stool Softener

Opioid Analgesic

Other Drugs

Aneurysmal Subarachnoid Hemorrhage Drugs Segment by Application

Hospital

Clinic

Others

Aneurysmal Subarachnoid Hemorrhage Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Aneurysmal Subarachnoid Hemorrhage Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Aneurysmal Subarachnoid Hemorrhage Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Aneurysmal Subarachnoid Hemorrhage Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Aneurysmal Subarachnoid Hemorrhage Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Aneurysmal Subarachnoid Hemorrhage Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Aneurysmal Subarachnoid Hemorrhage Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Aneurysmal Subarachnoid Hemorrhage Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Aneurysmal Subarachnoid Hemorrhage Drugs Industry Trends Table 2. Aneurysmal Subarachnoid Hemorrhage Drugs Industry Drivers Table 3. Aneurysmal Subarachnoid Hemorrhage Drugs Industry Opportunities and Challenges Table 4. Aneurysmal Subarachnoid Hemorrhage Drugs Industry Restraints Table 5. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Manufacturers (Tons) & (2021-2026) Table 8. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Manufacturers Table 9. Global Aneurysmal Subarachnoid Hemorrhage Drugs Average Sales Price (US$/Ton) of Manufacturers (2021-2026) Table 10. Global Aneurysmal Subarachnoid Hemorrhage Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Aneurysmal Subarachnoid Hemorrhage Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Aneurysmal Subarachnoid Hemorrhage Drugs Manufacturers, Product Type & Application Table 13. Global Aneurysmal Subarachnoid Hemorrhage Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Aneurysmal Subarachnoid Hemorrhage Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Osmotic Agent Table 17. Major Manufacturers of Anticonvulsant Table 18. Major Manufacturers of Calcium Channel Blocker Table 19. Major Manufacturers of Stool Softener Table 20. Major Manufacturers of Opioid Analgesic Table 21. Major Manufacturers of Other Drugs Table 22. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Type 2021 VS 2025 VS 2032 (Tons) Table 23. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Type (2021-2026) & (Tons) Table 24. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Type (2027-2032) & (Tons) Table 25. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Type (2021-2026) Table 26. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Type (2027-2032) Table 27. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Type 2021 VS 2025 VS 2032 (Tons) Table 28. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Type (2021-2026) & (Tons) Table 29. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Type (2027-2032) & (Tons) Table 30. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Type (2021-2026) Table 31. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Clinic Table 34. Major Manufacturers of Others Table 35. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Application 2021 VS 2025 VS 2032 (Tons) Table 36. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Application (2021-2026) & (Tons) Table 37. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Application (2027-2032) & (Tons) Table 38. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Application (2021-2026) Table 39. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Application (2027-2032) Table 40. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Application 2021 VS 2025 VS 2032 (Tons) Table 41. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Application (2021-2026) & (Tons) Table 42. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Application (2027-2032) & (Tons) Table 43. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Application (2021-2026) Table 44. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Application (2027-2032) Table 45. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 46. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Region (2021-2026) & (Tons) Table 47. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Region (2021-2026) Table 48. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecasted by Region (2027-2032) & (Tons) Table 49. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Aneurysmal Subarachnoid Hemorrhage Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 51. North America Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2021-2026) & (Tons) Table 52. North America Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2027-2032) & (Tons) Table 53. Europe Aneurysmal Subarachnoid Hemorrhage Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 54. Europe Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2021-2026) & (Tons) Table 55. Europe Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2027-2032) & (Tons) Table 56. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 57. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2021-2026) & (Tons) Table 58. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2027-2032) & (Tons) Table 59. South America, Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 60. South America, Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2021-2026) & (Tons) Table 61. South America, Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2027-2032) & (Tons) Table 62. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Region (2021-2026) Table 66. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Region (2027-2032) Table 67. Arbor Pharmaceuticals Company Information Table 68. Arbor Pharmaceuticals Business Overview Table 69. Arbor Pharmaceuticals Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Arbor Pharmaceuticals Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio Table 71. Arbor Pharmaceuticals Recent Development Table 72. Orexo AB Company Information Table 73. Orexo AB Business Overview Table 74. Orexo AB Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Orexo AB Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio Table 76. Orexo AB Recent Development Table 77. PDS Biotechnology Corporation Company Information Table 78. PDS Biotechnology Corporation Business Overview Table 79. PDS Biotechnology Corporation Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. PDS Biotechnology Corporation Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio Table 81. PDS Biotechnology Corporation Recent Development Table 82. Pharmaxis Company Information Table 83. Pharmaxis Business Overview Table 84. Pharmaxis Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Pharmaxis Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio Table 86. Pharmaxis Recent Development Table 87. Purdue Pharma Company Information Table 88. Purdue Pharma Business Overview Table 89. Purdue Pharma Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Purdue Pharma Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio Table 91. Purdue Pharma Recent Development Table 92. Pfizer Company Information Table 93. Pfizer Business Overview Table 94. Pfizer Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Pfizer Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio Table 96. Pfizer Recent Development Table 97. Mylan N.V Company Information Table 98. Mylan N.V Business Overview Table 99. Mylan N.V Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Mylan N.V Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio Table 101. Mylan N.V Recent Development Table 102. Johnson and Johnson Company Information Table 103. Johnson and Johnson Business Overview Table 104. Johnson and Johnson Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Johnson and Johnson Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio Table 106. Johnson and Johnson Recent Development Table 107. Sun Pharmaceutical Industries Company Information Table 108. Sun Pharmaceutical Industries Business Overview Table 109. Sun Pharmaceutical Industries Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Sun Pharmaceutical Industries Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio Table 111. Sun Pharmaceutical Industries Recent Development Table 112. Teva Pharmaceutical Company Information Table 113. Teva Pharmaceutical Business Overview Table 114. Teva Pharmaceutical Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Teva Pharmaceutical Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio Table 116. Teva Pharmaceutical Recent Development Table 117. Key Raw Materials Table 118. Raw Materials Key Suppliers Table 119. Aneurysmal Subarachnoid Hemorrhage Drugs Distributors List Table 120. Aneurysmal Subarachnoid Hemorrhage Drugs Customers List Table 121. Research Programs/Design for This Report Table 122. Authors List of This Report Table 123. Secondary Sources Table 124. Primary Sources List of Figures Figure 1. Aneurysmal Subarachnoid Hemorrhage Drugs Product Image Figure 2. Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales (2021-2032) & (Tons) Figure 5. Global Aneurysmal Subarachnoid Hemorrhage Drugs Average Price (US$/Ton) & (2021-2032) Figure 6. Global Top 5 and 10 Aneurysmal Subarachnoid Hemorrhage Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Osmotic Agent Image Figure 9. Anticonvulsant Image Figure 10. Calcium Channel Blocker Image Figure 11. Stool Softener Image Figure 12. Opioid Analgesic Image Figure 13. Other Drugs Image Figure 14. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Type (2021 VS 2025 VS 2032) & (Tons) Figure 15. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Type (2021-2032) Figure 17. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Type (2021 VS 2025 VS 2032) & (Tons) Figure 18. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Others Image Figure 23. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Application (2021 VS 2025 VS 2032) & (Tons) Figure 24. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Application (2021-2032) Figure 26. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Application (2021 VS 2025 VS 2032) & (Tons) Figure 27. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Application (2021-2032) Figure 29. North America Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 30. North America Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Country (2021-2032) Figure 31. U.S. Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 32. Canada Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 33. Mexico Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 34. Europe Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 35. Europe Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Country (2021-2032) Figure 36. Germany Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 37. France Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 38. U.K. Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 39. Italy Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 40. Netherlands Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 41. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 42. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Country (2021-2032) Figure 43. China Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 44. Japan Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 45. South Korea Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 46. Southeast Asia Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 47. India Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 48. Australia Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 49. South America, Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 50. South America, Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Country (2021-2032) Figure 51. Brazil Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 52. South Africa Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 53. Saudi Arabia Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 54. Turkey Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 55. Argentina Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 56. UAE Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 57. Egypt Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 58. Chile Aneurysmal Subarachnoid Hemorrhage Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 59. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (2021-2032) & (US$ Million) Figure 62. North America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Europe Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Aneurysmal Subarachnoid Hemorrhage Drugs Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Aneurysmal Subarachnoid Hemorrhage Drugs Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Osmotic Agent
  • Anticonvulsant
  • Calcium Channel Blocker
  • Stool Softener
  • Opioid Analgesic
  • Other Drugs
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Arbor Pharmaceuticals
  • Orexo AB
  • PDS Biotechnology Corporation
  • Pharmaxis
  • Purdue Pharma
  • Pfizer
  • Mylan N.V
  • Johnson and Johnson
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Dynamics
  1. 2.1 Aneurysmal Subarachnoid Hemorrhage Drugs Industry Trends
  2. 2.2 Aneurysmal Subarachnoid Hemorrhage Drugs Industry Drivers
  3. 2.3 Aneurysmal Subarachnoid Hemorrhage Drugs Industry Opportunities and Challenges
  4. 2.4 Aneurysmal Subarachnoid Hemorrhage Drugs Industry Restraints
3 Aneurysmal Subarachnoid Hemorrhage Drugs Market by Manufacturers
  1. 3.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Aneurysmal Subarachnoid Hemorrhage Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Aneurysmal Subarachnoid Hemorrhage Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Aneurysmal Subarachnoid Hemorrhage Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Aneurysmal Subarachnoid Hemorrhage Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Aneurysmal Subarachnoid Hemorrhage Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Aneurysmal Subarachnoid Hemorrhage Drugs Tier 1, Tier 2, and Tier 3
4 Aneurysmal Subarachnoid Hemorrhage Drugs Market by Type
  1. 4.1 Aneurysmal Subarachnoid Hemorrhage Drugs Type Introduction
  2. 4.1.1 Osmotic Agent
  3. 4.1.2 Anticonvulsant
  4. 4.1.3 Calcium Channel Blocker
  5. 4.1.4 Stool Softener
  6. 4.1.5 Opioid Analgesic
  7. 4.1.6 Other Drugs
  8. 4.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Type
  9. 4.2.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Type (2021-2032)
  11. 4.2.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Type (2021-2032)
  12. 4.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Type
  13. 4.3.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Type (2021-2032)
  15. 4.3.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Type (2021-2032)
5 Aneurysmal Subarachnoid Hemorrhage Drugs Market by Application
  1. 5.1 Aneurysmal Subarachnoid Hemorrhage Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Application
  6. 5.2.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Application
  10. 5.3.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Application (2021-2032)
6 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Region
  1. 6.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Aneurysmal Subarachnoid Hemorrhage Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Region
  1. 7.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Region
  2. 7.1.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (2021-2032)
  8. 7.2.2 North America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Arbor Pharmaceuticals
  2. 8.1.1 Arbor Pharmaceuticals Company Information
  3. 8.1.2 Arbor Pharmaceuticals Business Overview
  4. 8.1.3 Arbor Pharmaceuticals Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Arbor Pharmaceuticals Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
  6. 8.1.5 Arbor Pharmaceuticals Recent Developments
  7. 8.2 Orexo AB
  8. 8.2.1 Orexo AB Company Information
  9. 8.2.2 Orexo AB Business Overview
  10. 8.2.3 Orexo AB Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Orexo AB Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
  12. 8.2.5 Orexo AB Recent Developments
  13. 8.3 PDS Biotechnology Corporation
  14. 8.3.1 PDS Biotechnology Corporation Company Information
  15. 8.3.2 PDS Biotechnology Corporation Business Overview
  16. 8.3.3 PDS Biotechnology Corporation Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 PDS Biotechnology Corporation Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
  18. 8.3.5 PDS Biotechnology Corporation Recent Developments
  19. 8.4 Pharmaxis
  20. 8.4.1 Pharmaxis Company Information
  21. 8.4.2 Pharmaxis Business Overview
  22. 8.4.3 Pharmaxis Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pharmaxis Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
  24. 8.4.5 Pharmaxis Recent Developments
  25. 8.5 Purdue Pharma
  26. 8.5.1 Purdue Pharma Company Information
  27. 8.5.2 Purdue Pharma Business Overview
  28. 8.5.3 Purdue Pharma Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Purdue Pharma Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
  30. 8.5.5 Purdue Pharma Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Mylan N.V
  38. 8.7.1 Mylan N.V Company Information
  39. 8.7.2 Mylan N.V Business Overview
  40. 8.7.3 Mylan N.V Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Mylan N.V Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
  42. 8.7.5 Mylan N.V Recent Developments
  43. 8.8 Johnson and Johnson
  44. 8.8.1 Johnson and Johnson Company Information
  45. 8.8.2 Johnson and Johnson Business Overview
  46. 8.8.3 Johnson and Johnson Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Johnson and Johnson Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
  48. 8.8.5 Johnson and Johnson Recent Developments
  49. 8.9 Sun Pharmaceutical Industries
  50. 8.9.1 Sun Pharmaceutical Industries Company Information
  51. 8.9.2 Sun Pharmaceutical Industries Business Overview
  52. 8.9.3 Sun Pharmaceutical Industries Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sun Pharmaceutical Industries Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
  54. 8.9.5 Sun Pharmaceutical Industries Recent Developments
  55. 8.10 Teva Pharmaceutical
  56. 8.10.1 Teva Pharmaceutical Company Information
  57. 8.10.2 Teva Pharmaceutical Business Overview
  58. 8.10.3 Teva Pharmaceutical Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Teva Pharmaceutical Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
  60. 8.10.5 Teva Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Aneurysmal Subarachnoid Hemorrhage Drugs Value Chain Analysis
  2. 9.1.1 Aneurysmal Subarachnoid Hemorrhage Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Aneurysmal Subarachnoid Hemorrhage Drugs Production Mode & Process
  6. 9.2 Aneurysmal Subarachnoid Hemorrhage Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Aneurysmal Subarachnoid Hemorrhage Drugs Distributors
  9. 9.2.3 Aneurysmal Subarachnoid Hemorrhage Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst